Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Status:
Not yet recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

This is a multicenter, randomized, controlled, phase III study.

Phase 3

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Carboplatin
Pemetrexed